Regeneron Pharmaceuticals, Inc. unveiled new data for REGN7075, a EGFRxCD28-directed costimulatory bispecific antibody, at the American Society of Clinical Oncology (ASCO) meeting. The early data suggested modest efficacy in a difficult-to-treat cancer type and also showed decent tolerability, offering new insight into CD28 as a target for cancer.
The information is valuable to Regeneron because REGN7075 is just one of several bispecific antibodies it is developing targeting CD28 and the company has
REGN7075 is one approach among a much larger suite of bispecific antibodies in development by Regeneron, the centerpiece of its oncology development strategy